Evidence map›Paper›PMID 22194994›Full record

ArticlePloS one2011

Identification of novel androgen-regulated pathways and mRNA isoforms through genome-wide exon-specific profiling of the LNCaP transcriptome.

Prabhakar Rajan, Caroline Dalgliesh, Phillippa J Carling, Thomas Buist, Chaolin Zhang, Sushma N Grellscheid, Kelly Armstrong, Jacqueline Stockley, Cedric Simillion, Luke Gaughan and 5 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 42 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Prabhakar RajanInstitute of Human Genetics, Newcastle University, Newcastle-upon-Tyne, United Kingdom.
Caroline Dalgliesh
Phillippa J Carling
Thomas Buist
Chaolin Zhang
Sushma N Grellscheid
Kelly Armstrong
Jacqueline Stockley
Cedric Simillion
Luke Gaughan
Gabriela Kalna
Michael Q Zhang
Craig N Robson
Hing Y Leung
David J Elliott
Newcastle University · GBCold Spring Harbor Laboratory · USUniversity of Glasgow · GBCancer Research UK Scotland Institute · GB

Funding

Computational and experimental modeling of RNA SplicingR01GM074688 · NIGMS · UNIVERSITY OF TEXAS DALLAS · PI ZHANG, MICHAEL Q · 2007 to 2012
$1.6M
Cancer Research UK 15151Medical Research Council G0500482NIGMS NIH HHS GM074688NIGMS NIH HHS R01 GM074688Wellcome TrustWellcome Trust 080388Worldwide Cancer Research 06-0705
6 · The paper itself

Abstract

Androgens drive the onset and progression of prostate cancer (PCa) by modulating androgen receptor (AR) transcriptional activity. Although several microarray-based studies have identified androgen-regulated genes, here we identify in-parallel global androgen-dependent changes in both gene and alternative mRNA isoform expression by exon-level analyses of the LNCaP transcriptome. While genome-wide gene expression changes correlated well with previously-published studies, we additionally uncovered a subset of 226 novel androgen-regulated genes. Gene expression pathway analysis of this subset revealed gene clusters associated with, and including the tyrosine kinase LYN, as well as components of the mTOR (mammalian target of rapamycin) pathway, which is commonly dysregulated in cancer. We also identified 1279 putative androgen-regulated alternative events, of which 325 (∼25%) mapped to known alternative splicing events or alternative first/last exons. We selected 30 androgen-dependent alternative events for RT-PCR validation, including mRNAs derived from genes encoding tumour suppressors and cell cycle regulators. Of seven positively-validating events (∼23%), five events involved transcripts derived from alternative promoters of known AR gene targets. In particular, we found a novel androgen-dependent mRNA isoform derived from an alternative internal promoter within the TSC2 tumour suppressor gene, which is predicted to encode a protein lacking an interaction domain required for mTOR inhibition. We confirmed that expression of this alternative TSC2 mRNA isoform was directly regulated by androgens, and chromatin immunoprecipitation indicated recruitment of AR to the alternative promoter region at early timepoints following androgen stimulation, which correlated with expression of alternative transcripts. Together, our data suggest that alternative mRNA isoform expression might mediate the cellular response to androgens, and may have roles in clinical PCa.

Indexed as

Gene Expression ProfilingAndrogensCell Line, TumorEpithelial CellsExonsGene Expression Regulation, NeoplasticGenes, NeoplasmGenome, HumanHumansLigandsMalePromoter Regions, GeneticProstatic NeoplasmsReceptors, AndrogenRNA IsoformsSignal TransductionAndrogensAR protein, humanLigandsReceptors, AndrogenRNA IsoformsTSC2 protein, humanTuberous Sclerosis Complex 2 ProteinTumor Suppressor Proteins

Identifiers

PMID22194994
PMCPMC3237596
OpenAlexW2161803073

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.